Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 6/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.38 |
| ▸ | AGPAT2 | O15120 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1284860 | 0.89 | AGPAT2 (0.46) | PDE2ACCNB2CDK1CCNB1GSK3B | |
| SCHEMBL1284052 | 0.88 | CRBN (0.39) | PDE2APDE10ABRD4CCNB2CDK1 | |
| SCHEMBL1284922 | 0.87 | TBXA2R (0.40) | PDE2ACCNB2CDK1CCNB1GSK3B | |
| SCHEMBL1284738 | 0.85 | PDE2A (0.45) | PDE2APDE10ACCNB2CDK1CCNB1 | |
| SCHEMBL1284166 | 0.81 | PDE2A (0.40) | PDE2APDE10ACCNB2CDK1CCNB1 | |
| SCHEMBL1283797 | 0.80 | PIK3CA (0.41) | PDE2ACCNB2CDK1CCNB1GSK3B | |
| SCHEMBL6742849 | 0.79 | ALDH1A1 (0.45) | BRD4ALDH1A1 | |
| SCHEMBL1624507 | 0.78 | AGPAT2 (0.49) | PDE2APDE10AAGPAT2ALDH1A1 | |
| SCHEMBL1284398 | 0.77 | MAPT (0.43) | ALDH1A1 | |
| SCHEMBL13049947 | 0.76 | AGPAT2 (0.46) | PDE2AAGPAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835648-B2 | Hedgehog pathway antagonists and therapeutic applications thereof | SIENA BIOTECH S.P.A. (IT) | 2014-09-16 | — | — | US | disclosed |
| US-8835648-B2 | Hedgehog pathway antagonists and therapeutic applications thereof | SIENA BIOTECH S.P.A. (IT) | 2014-09-16 | — | — | US | disclosed |
| EP-2440544-B1 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF | SIENA BIOTECH SPA (IT) | 2013-08-14 | — | — | EP | disclosed |
| EP-2440544-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF | Siena Biotech S.p.A. (IT) | 2012-04-18 | — | — | EP | disclosed |
| US-20120088752-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF | SIENA BIOTECH S.P.A. (IT) | 2012-04-12 | — | — | US | disclosed |
| US-20120088752-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF | SIENA BIOTECH S.P.A. (IT) | 2012-04-12 | — | — | US | disclosed |
| WO-2010142426-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF | SIENA BIOTECH S.P.A. (IT) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088752-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF | SHH, GLI1, SMO | PDE2A 2811/4885PDE10A 2205/4885BRD4 458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.